Immix Biopharma Inc
NASDAQ:IMMX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Immix Biopharma Inc
NASDAQ:IMMX
|
US |
|
Theravance Biopharma Inc
NASDAQ:TBPH
|
KY |
|
H
|
Hankuk Steel Wire Co Ltd
KOSDAQ:025550
|
KR |
|
Aerometrex Ltd
ASX:AMX
|
AU |
|
W
|
Wanted Lab Inc
KOSDAQ:376980
|
KR |
|
Colgate-Palmolive Co
NYSE:CL
|
US |
|
Astrotech Corp
F:SP5
|
US |
|
Yunfeng Financial Group Ltd
F:MNA1
|
HK |
|
E
|
Entravision Communications Corp
F:EV9
|
US |
Intrinsic Value
Is IMMX undervalued or overvalued?
See the intrinsic value estimate for Immix Biopharma Inc and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
IMMX looks undervalued.
But is it cheap by its own standards?
See how today’s valuation compares with IMMX’s past valuations and how the stock performed after similar periods.
Fundamental Analysis
What Immix Biopharma Does
Immix Biopharma is a clinical-stage biotech company developing cancer and blood-disease therapies, not a company with approved drugs on the market. Its main work is on NXC-201, a CAR-T cell therapy aimed at hard-to-treat plasma cell diseases such as multiple myeloma and AL amyloidosis, along with IMX-110, a tissue-targeted drug candidate for solid tumors. These are experimental medicines designed to attack diseased cells more precisely than older treatments.
- Headquarters
- United States of America US
- Employees
- 21
- IPO date
- Dec 16, 2021
Immix Biopharma has no economic moat
Immix Biopharma Inc lacks an economic moat, leaving it vulnerable to competitive pressures and market challenges.
Read the full moat analysis
Earnings Waterfall
Immix Biopharma Inc
The intrinsic value for Immix Biopharma Inc (IMMX) under the Base Case is hidden USD.
Compared with the current market price of 8.35 USD, the stock appears hidden.